Regarding treatment, obesity may also undermine the response to endocrine therapy in premenopausal patients [35] and tamoxifen treatment in postmenopausal patients with ER+ tumors [33, 36]. This evidence concerns the gene ESR1 and obesity due to melanocortin 4 receptor deficiency.